LeenaGandhiMD

Oncology • Boston, MA

Associate Professor, Dana-Farber Cancer Institute, Harvard Medical School

Join to view full profile

Dr. Gandhi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gandhi's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2008
Massachusetts General HospitalResidency, Internal Medicine, 2002 - 2004
New York University School of MedicineClass of 2002

Certifications & Licensure

MA State Medical License 2005 - 2025
NY State Medical License 2016 - 2023

Clinical Trials

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2010 Jul 28
Completed
Phase 2
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2010 Jun 01
Completed
Phase 2
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01
Completed
Phase 1
AUY922 for Advanced ALK-positive NSCLC Start of enrollment: 2013 Jan 01
Completed
Phase 2
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR Start of enrollment: 2013 Jul 01
Completed
Phase 2
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Start of enrollment: 2015 Oct 13
Active, not recruiting
Phase 1, Phase 2
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer Start of enrollment: 2018 Mar 30
Terminated
Phase 2
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) Start of enrollment: 2017 Jan 23
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study.
Tali Mazor, Pavel Trukhanov, James Lindsay, Matthew R Galvin, Karim S Farhat, Emily McClure, Ethan Cerami, Kenneth L Kehl, Antonio Giordano, Leena Gandhi, Deborah Schr...> ;JCO Precision Oncology. 2024 Mar 1
15 citations
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
H Park, G I Shapiro, X Gao, A Mahipal, J Starr, M Furqan, P Singh, A Ahrorov, L Gandhi, A Ghosh, D Hickman, P D Gallacher, A Wennborg, E C Attar, M M Awad, S Das, E E ...> ;ESMO Open. 2022 Oct 1
18 citations
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.
Timothy A. Yap, Maria Vieito, Capucine Baldini, Juan M. Sepúlveda-Sánchez, Shunsuke Kondo, Matteo Simonelli, Rasha Cosman, Andre van der Westhuizen, Victoria Atkinson,...> ;Clinical Cancer Research. 2021 Sep 21
26 citations
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repa...
Antoine Hollebecque, Hyun Cheol Chung, Maria de Miguel, Antoine Italiano, Jean-Pascal Machiels, Chai-Chi Lin, Neesha C. Dhani, Marc Peeters, Victor Moreno, Wu Chou Su,...> ;Clinical Cancer Research. 2021 Aug 30
11 citations
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Nuria Kotecki, P. Vuagnat, Bert H. O'Neil, Shadia I. Jalal, Sylvie Rottey, Hans Prenen, Karim A. Benhadji, Meng Xia, Anna M. Szpurka, Abhijoy Saha, Johan Wallin, Subha...> ;Journal of Immunotherapy. 2021 Apr 28
85 citations
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Davide Melisi, Do Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna M. Varghese, Erkut Borazanci, Teresa Macarulla, Valeria Merz, Camilla Zecchetto, Yumin Zhao, Iveli...> ;Journal for Immunotherapy of Cancer. 2021 Mar 1
23 citations
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Maria de Miguel, Yung Jue Bang, Chia-Chi Lin, Wu Chou Su, Antoine Italiano, Kay Hoong Chow, Anna M. Szpurka, Danni Yu,...> ;Clinical Cancer Research. 2021 Mar 1
54 citations
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.
James J. Harding, Victor Moreno, Yung Jue Bang, Min Hee Hong, Amita Patnaik, Jose Manuel Trigo, Anna M. Szpurka, Noboru Yamamoto, Toshihiko Doi, Siqing Fu, Boris Calde...> ;Clinical Cancer Research. 2021 Apr 15
44 citations
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Matthew D. Hellmann, Nicoletta Bivi, Boris Calderon, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, F. Stephen Hodi, Sylvie ...> ;Clinical Cancer Research. 2021 May 15
39 citations
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.
Stefan Zimmerman, Arundhati Das, Shuhang Wang, Ricklie Ann Julian, Leena Gandhi, Juergen Wolf> ;Journal of Thoracic Oncology. 2019 May 1
80 citations
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Al...
Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric-Bernstam, Josep Tabernero, Filip Janku, Leena Gandhi, A. John Iafrate, Darrell R. Borger, ...> ;Clinical Cancer Research. 2019 May 1
60 citations
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
Matthew A. Gubens, Lecia V. Sequist, James P. Stevenson, Steven Francis Powell, Liza C. Villaruz, Shirish M. Gadgeel, Corey J. Langer, Amita Patnaik, Hossein Borghaei,...> ;Lung Cancer. 2019 Apr 1
59 citations
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
Alison M. Schram, Leena Gandhi, Monica M. Mita, Lars Damstrup, Frank Campana, Manuel Hidalgo, Enrique Grande, David M. Hyman, Rebecca S. Heist> ;British Journal of Cancer. 2018 Nov 14
59 citations
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
Shirish M. Gadgeel, James P. Stevenson, Corey J. Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza C. Villaruz, Matthew A. Gubens, Ralph Hauke, James Chih-Hs...> ;Lung Cancer. 2018 Nov 1
64 citations
Emerging biomarkers for immune checkpoint inhibition in lung cancer
George Cyriac, Leena Gandhi> ;Seminars in Cancer Biology. 2018 Oct 1
Pembrolizumab plus Chemotherapy in Lung Cancer.
Gandhi, L., Garassino, M. C.> ;The New England journal of medicine. 2018 Sep 13
154 citations
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small ...
Hossein Borghaei, Corey J. Langer, Shirish M. Gadgeel, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Francis Powell, Ryan D. Gentzler, Renato G. Martins, Jam...> ;Journal of Thoracic Oncology. 2019 Jan 1
39 citations
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
Leora Horn, Scott N. Gettinger, Michael S. Gordon, Roy S. Herbst, Leena Gandhi, Enriqueta Felip, Lecia V. Sequist, David R. Spigel, Scott J. Antonia, Ani Sarkis Balman...> ;European Journal of Cancer. 2018 Aug 1
154 citations
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. G...> ;Journal for Immunotherapy of Cancer. 2018 Jul 17
7 citations
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer.
Sai-Hong Ignatius Ou, Mark A. Socinski, Shirish M. Gadgeel, Leena Gandhi, Howard West, Alberto Chiappori, Victor Cohen, Gregory J. Riely, Vlatka Smoljanovic, Walter Bo...> ;ESMO Open. 2018 Jul 1
Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.
Leena Gandhi> ;Clinical Advances in Hematology & Oncology. 2018 Jul 1
41 citations
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Glenwood D. Goss, Everett E. Vokes, Michael S. Gordon, Leena Gandhi, Kyriakos P. Papadopoulos, Drew W. Rasco, JuDee Fischer, Katharine L. Chu, William Ames, Rajendar K...> ;Cancer. 2018 May 15
3828 citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodriguez-Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J. Hochmair, St...> ;The New England Journal of Medicine. 2018 Apr 16
54 citations
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
Enriqueta Felip, Fabrice Barlesi, Benjamin Besse, Quincy Chu, Leena Gandhi, Sang-We Kim, Enric Carcereny, Lecia V. Sequist, Paal Brunsvig, Christos Chouaid, Egbert F. ...> ;Journal of Thoracic Oncology. 2017 Dec 13
95 citations
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub, D. Ross Camidge, Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Char...> ;Clinical Cancer Research. 2017 Oct 1
Join now to see all

Lectures

Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

NexImmune Announces Appointment of Dr. Leena Gandhi to Its Board of DirectorsMay 10th, 2022
Bright Peak Therapeutics Appoints Leena Gandhi, M.D., Ph.D., to Its Board of DirectorsFebruary 28th, 2022
Lung Cancer Awareness Month: 2021 Immunotherapy Research UpdatesNovember 1st, 2021
Join now to see all